DaVita DVA
Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. 10-K, Item 1
- Headquarters
- Denver, CO
- CEO
- Javier Rodriguez
- Next results
- around Feb 1, 2027
DVA among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.
What changed
29 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 11, 2026 against Feb 13, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Inventory growing faster than revenueInventory +19.4% vs revenue +6.5% (+12.9 pts)
-
Receivables +12.5% vs revenue +6.5% (+6.0 pts)
9 more checks with nothing to note
-
Cash from operations $1.9B vs net income $746.8M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: U.S. dialysis patient service revenue recognition; F-2; Evaluation of legal proceedings and regulatory matters
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
29 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Risks Related to Competition, Business Strategy Growth, Information Systems and New Technologies
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Global health conditions, changing population or demographic trends, severe weather events or natural disasters and general economic and political conditions, all of which are highly uncertain and difficult to predict, could have a material adverse impact on our business. We continue to be impacted by external conditions, including, but…
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Global health conditions may adversely impact our patient census and treatment volumes. For example, severe flu seasons and the ongoing incidence of other infectious diseases such as COVID-19 in recent years have driven elevated mortality in our patient population, which has in turn had a negative impact on treatment volume. The…
-
Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
Severe weather events or natural or other disasters such as hurricanes, earthquakes, fires or flooding that damage, destroy or limit access to our facilities or impact our key suppliers or service providers could adversely impact our operations. In the past, such severe weather events or natural disasters impacting us or our suppliers…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $11.6B | $12.1B | $12.8B | $13.6B |
| Net income | $560.4M | $691.5M | $936.3M | $746.8M |
| Operating cash flow | $1.6B | $2.1B | $2.0B | $1.9B |
| Free cash flow | $961.1M | $1.5B | $1.5B | $1.3B |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$13.6B ▲ 6.5% in FY2025$746.8M ▼ 20.2% in FY2025$1.3B ▼ 10.6% in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleOct 29, 2026Javier Rodriguez (Chief Executive Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 115,810 shares, runs to Aug 26, 2027
-
8-KOct 29, 2026Quarterly results 8-K item 2.02
-
10-QOct 29, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
DaVita, Denver, CO · from the 10-K filed Feb 11, 2026
Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC).
- Headquarters
- Denver, CO
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Oct 29, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 11, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/DVA/export.csv") into a cell.